This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Feiring, B. Articles by Aaberge, I. S. Search for Related Content PubMed PubMed Citation Articles by Feiring, B. Articles by Aaberge, I. S.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, July 2006, p. 790-796, Vol. 13, No. 7
1071-412X/06/$08.00+0     doi:10.1128/CVI.00047-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Persisting Immune Responses Indicating Long-Term Protection after Booster Dose with Meningococcal Group B Outer Membrane Vesicle Vaccine

Berit Feiring,^1* Jan Fuglesang,^1, Philipp Oster,² Lisbeth M. Næss,¹ Oddveig S. Helland,¹ Sandrine Tilman,³ Einar Rosenqvist,¹ Marianne A. R. Bergsaker,¹ Hanne Nøkleby,¹ and Ingeborg S. Aaberge¹

Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway,¹ Chiron Srl, Siena, Italy,² Chiron B.V., Amsterdam, The Netherlands³

Received 6 February 2006/ Returned for modification 8 March 2006/ Accepted 27 April 2006

MenBvac is an outer membrane vesicle vaccine against systemic meningococcal disease caused by serogroup B Neisseria meningitidis. In this placebo-controlled double-blind study including 374 healthy adolescents, the safety and immunogenicity of a schedule of three primary doses 6 weeks apart followed by a fourth dose a year later were evaluated. Antibody responses to the vaccine strain and heterologous strains (non-vaccine-type strains) and the persistence of these antibodies were measured by the serum bactericidal assay (SBA) and enzyme-linked immunosorbent assay up to 1 year after the last dose. The proportion of subjects with SBA titers of 4 against the vaccine strain increased from 3% prevaccination to 65% after the third dose. Ten months later, this proportion had declined to 28%. The fourth dose induced a booster response demonstrated by 93% of subjects achieving a titer of 4. One year after the booster dose, 64% still showed SBA titers of 4. Cross-reacting antibodies were induced against all heterologous strains tested, although the magnitude of SBA titers differed widely between the different strains. All four doses of MenBvac were safe. Both MenBvac and the placebo had reactogenicity profiles of mild to moderate local and systemic reactions. Pain, the most common reaction, was reported with similar frequencies in both groups. No serious adverse events occurred in the MenBvac group. This study confirmed the good immunogenicity of the primary course of MenBvac and demonstrated prolonged persistence and increased cross-reactivity of functional antibodies elicited by a booster dose.

Present address: Directorate for Health and Social Affairs, Oslo, Norway.

This article has been cited by other articles:

• Alaniz, R. C., Deatherage, B. L., Lara, J. C., Cookson, B. T. (2007). Membrane Vesicles Are Immunogenic Facsimiles of Salmonella typhimurium That Potently Activate Dendritic Cells, Prime B and T Cell Responses, and Stimulate Protective Immunity In Vivo. J. Immunol. 179: 7692-7701 [Abstract] [Full Text]  
• Hosking, J., Rasanathan, K., Mow, F. C., Jackson, C., Martin, D., O'Hallahan, J., Oster, P., Ypma, E., Reid, S., Aaberge, I., Crengle, S., Stewart, J., Lennon, D. (2007). Immunogenicity, Reactogenicity, and Safety of a P1.7b,4 Strain-Specific Serogroup B Meningococcal Vaccine Given to Preteens. CVI 14: 1393-1399 [Abstract] [Full Text]  
• Sandbu, S., Feiring, B., Oster, P., Helland, O. S., Bakke, H. S. W., Naess, L. M., Aase, A., Aaberge, I. S., Kristoffersen, A.-C., Rydland, K. M., Tilman, S., Nokleby, H., Rosenqvist, E. (2007). Immunogenicity and Safety of a Combination of Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines. CVI 14: 1062-1069 [Abstract] [Full Text]